Obinutuzumab
Monoclonal antibody
Evidence outlook
Approved: Chronic Lymphocytic Leukemia, Follicular Lymphoma, Lupus Nephritis, Primary Membranous Nephropathy
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also in development:Non-Hodgkin Lymphoma · Phase 3
Also approved (5)
- To reduce the risk of relapse in adult and pediatric patients 2 years of age and older with frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome who are in complete remission
- GAZYVA is indicated to reduce the risk of relapse in adult and pediatric patients 2 years of age and older with frequently relapsing or steroid dependent childhood-onset idiopathic nephrotic syndrome who are in complete remission.
- in combination with mycophenolate mofetil for adult patients with active Class III or IV, with or without concomitant Class V, lupus nephritis
- Chronic lymphocytic leukaemia (CLL) Gazyvaro in combination with chlorambucil is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy. Follicular Lymphoma (FL) Gazyvaro in combination with chemotherapy, followed by Gazyvaro maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced follicular lymphoma. Gazyvaro in combination with bendamustine followed by Gazyvaro maintenance is...
- Treatment of CD20-positive follicular lymphoma
Company guidance: data expected November 2026 (NCT04629248; Roche, 23 Jul 2026). “The priority review is based on the positive phase III MAJESTY results, which show superiority of Gazyva/Gazyvaro over an immunosuppressive therapy, tacrolimus, in adults with pMN. 1 The FDA has already granted Breakthrough Therapy Designation (BTD) to Gazyva/Gazyvaro in pMN and is expected to make a decision on approval by November 2026.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT01010061 NCT01010061 · Lymphocytic Leukemia, Chronic Patients were randomly assigned to obinutuzumab plus chlorambucil or chlorambucil alone, but the study was open-label rather than double-blinded. The primary clinical endpoint, progression-free survival, was met, with 31.1 versus 11.1 months and p<0.0001; the substantial randomized sample supports reliable evidence, while the lack of blinding limits the overall strength rating. Registry: NCT01010061 | 3 | Progression-free Survival (PFS) (Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)); Percentage of Participants With Progression Free Survival Events (Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)) 2012-07-01 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
View 1 more trial
CRISTALLO NCT04285567 · Chronic Lymphocytic Leukemia (CLL) This was a randomized, open-label, active-controlled Phase 3 trial in 166 patients with previously untreated CLL, comparing venetoclax plus obinutuzumab (the experimental arm) with FCR/BR chemoimmunotherapy. The primary endpoint — MRD negativity in peripheral blood at Month 15, a surrogate biomarker rather than a hard clinical outcome — was met, with 81.3% versus 54.7% (p=0.0004). The open-label design and use of a surrogate primary endpoint limit the strength of the evidence despite the positive result. Registry: NCT04285567 | 3 | Minimal Residual Disease (MRD) Response Rate Measured in Peripheral Blood (PB) Using Next Generation Sequencing (NGS) (At Month 15) 2024-03-19 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (36)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (3)
What this study did
What this study did
What this study did
Phase 2 (163)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (44)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (65)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (2)
What this study did
What this study did
Early phase / not applicable (3)
What this study did
What this study did
What this study did
Used as active comparator (7)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (1)
What this study did
Phase 1 (1)
What this study did
Appears in other studies (3)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (2)
What this study did
What this study did
Phase 2 (1)
What this study did
Competitive landscape
Other CD20 drugs
Ocrelizumab, Ocrevus Zunovo, Ofatumumab, PF-05280586, Rituximab and 10 more. Compare all 16 CD20 drugs
This mechanism is crowded: 15 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Chronic Lymphocytic Leukemia: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Obinutuzumab: this drug | Approved | Monoclonal antibody | CD20 | Partial signal | No reviewed efficacy summary in this indication | |
| Acalabrutinib | Approved | Small molecule | BTK | Partial signal | Featured results are non-efficacy only in this race | |
| Alemtuzumab | Approved | Monoclonal antibody | CD52 | not yet graded | No reviewed efficacy summary in this indication | |
| Ibrutinib | Approved | Small molecule | BTK | Partial signal | NCT01611090: Progression-free Survival (PFS) (Up to 5 years): Ibrutinib+BR 65.12 Months | Placebo+BR 14.32 Months (95% CI 13.86 to 16.62) | |
| Ocrelizumab | Approved(overall) | Monoclonal antibody | CD20 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Ocrevus Zunovo | Approved(overall) | Monoclonal antibody | CD20 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Ofatumumab | Approved(overall) | Monoclonal antibody | CD20 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| PF-05280586 | Approved | Biologic (subtype unspecified) | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Pirtobrutinib | Approved | Small molecule | BTK | Partial signal | Featured results are non-efficacy only in this race | |
| Rituximab (Rituxan) | Approved | Monoclonal antibody | CD20, CD20-directed Cytolytic Antibody | not yet graded | No reviewed efficacy summary in this indication | |
| Rituximab-Abbs (Truxima) | Approved | Monoclonal antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Ublituximab (Briumvi) | Approved(overall) | Monoclonal antibody | CD20 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Venetoclax | Approved | Small molecule | BCL-2 | Partial signal | NCT02005471: Investigator-assessed PFS, venetoclax-rituximab vs bendamustine-rituximab: 2-year rates 84.9% vs 36.3% (hazard ratio 0.17; P<0.001) | |
| Zanubrutinib (Brukinsa) | Approved | Small molecule | BTK | Partial signal | NCT03734016: Overall response rate, zanubrutinib (n=327) vs ibrutinib (n=325): by independent review 86.2% vs 75.7%, response ratio 1.14 (95% CI 1.05 to 1.22), non-inferiority p<0.0001, superiority p=0.0007; by investigator 83.5% vs 74.2%, response ratio 1.12 (95% CI 1.04 to 1.22), non-inferiority p<0.0001, superiority p=0.0035 (CT.gov posted results). | |
| ABP 692 | Phase 3(overall) | Monoclonal antibody | CD20 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Acellbia | Phase 3(overall) | Monoclonal antibody | CD20 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| BCD-281 | Phase 3(overall) | Monoclonal antibody | CD20 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Bexobrutideg | Phase 3 | Small molecule | Bruton's tyrosine kinase (BTK) | not yet graded | No reviewed efficacy summary in this indication | |
| CT-P53 | Phase 3(overall) | Monoclonal antibody | CD20 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Divozilimab (Ivlizi) | Phase 3(overall) | Monoclonal antibody | CD20 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| HLX01 (Hanlikang) | Phase 3(overall) | Monoclonal antibody | CD20 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Nemtabrutinib | Phase 3 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Sonrotoclax (Beqalzi) | Phase 3 | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication | |
| Mesutoclax | Phase 2/3 | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication | |
| MS-553 | Phase 1/2 | Small molecule | Protein kinase C-beta (PKC-beta) | not yet graded | No reviewed efficacy summary in this indication | |
| SAR448501 | Phase 1(overall) | Multispecific antibody | CD20 | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(134 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Obinutuzumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (8)
November 2026 (2)
December 2026 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2027 (53)
January 2027 (3)
What to watch
What to watch
What to watch
February 2027 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
March 2027 (4)
What to watch
What to watch
What to watch
What to watch
April 2027 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
May 2027 (1)
What to watch
June 2027 (8)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
July 2027 (10)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
August 2027 (5)
What to watch
What to watch
What to watch
What to watch
September 2027 (3)
What to watch
What to watch
What to watch
October 2027 (1)
What to watch
November 2027 (1)
What to watch
December 2027 (7)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2028 (42)
January 2028 (4)
What to watch
What to watch
What to watch
What to watch
March 2028 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
April 2028 (3)
What to watch
What to watch
What to watch
May 2028 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
June 2028 (2)
July 2028 (4)
What to watch
What to watch
What to watch
What to watch
August 2028 (1)
What to watch
September 2028 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
October 2028 (2)
November 2028 (2)
December 2028 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2029 (16)
January 2029 (1)
What to watch
February 2029 (1)
What to watch
March 2029 (4)
What to watch
What to watch
What to watch
What to watch
April 2029 (1)
What to watch
June 2029 (2)
July 2029 (2)
September 2029 (2)
November 2029 (1)
What to watch
2030 (5)
January 2030 (2)
What to watch
What to watch
July 2030 (2)
November 2030 (1)
What to watch
2031 (4)
April 2031 (1)
What to watch
June 2031 (1)
What to watch
July 2031 (1)
What to watch
December 2031 (1)
What to watch
2032 (3)
January 2032 (1)
What to watch
April 2032 (1)
What to watch
May 2032 (1)
What to watch
2033 (2)
May 2033 (1)
What to watch
November 2033 (1)
What to watch
2037 (1)
November 2037 (1)
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent